Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7731448 | 0.97 | — | — | |
| SCHEMBL9407567 | 0.77 | — | — | |
| SCHEMBL11192907 | 0.76 | — | — | |
| SCHEMBL497295 | 0.76 | BTN3A1 (0.40) | CA2LPAR3LPAR1LPAR2 | |
| SCHEMBL1514200 | 0.76 | — | — | |
| SCHEMBL3693478 | 0.76 | CA2 (0.50) | CA2 | |
| SCHEMBL10285180 | 0.76 | — | — | |
| Phosphoric Acid SCHEMBL26662209 | 0.74 | CA2 (0.40) | CA2LPAR3LPAR1LPAR2FDPS | |
| SCHEMBL8849969 | 0.74 | — | — | |
| SCHEMBL21357002 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163252-A4 | COMPOSITIONS, KITS, AND METHODS RELATING TO THE HUMAN FEZ1 GENE, A NOVEL TUMOR SUPPRESSOR GENE | UNIV JEFFERSON (US) | 2004-04-07 | — | — | EP | claimed |
| EP-1163252-A2 | COMPOSITIONS, KITS, AND METHODS RELATING TO THE HUMAN FEZ1 GENE, A NOVEL TUMOR SUPPRESSOR GENE | Thomas Jefferson University (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000050565-A2 | COMPOSITIONS, KITS, AND METHODS RELATING TO THE HUMAN FEZ1 GENE, A NOVEL TUMOR SUPPRESSOR GENE | THOMAS JEFFERSON UNIVERSITY (US) | 2000-08-31 | — | — | WO | claimed |
| US-20230338557-A1 | ENHANCED DNA DENDRIMERS AND METHODS OF USE THEREOF | CODE BIOTHERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023154788-A2 | ENHANCED DNA DENDRIMERS AND METHODS OF USE THEREOF | CODE BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230015276-A1 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220242964-A1 | COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2022-08-04 | — | — | US | disclosed |
| US-11390885-B2 | Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| US-11147828-B2 | Let-7 microRNA and mimetics thereof as therapeutics for cancer | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| US-11117976-B2 | Compositions and methods for regulating erythropoiesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3258958-B1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RHINOVIRUS INFECTIONS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2000043044-A1 | COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY OF VIRUS VECTORS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000041732-A1 | HYDROGEL COMPOSITIONS FOR CONTROLLED DELIVERY OF VIRUS VECTORS AND METHODS OF USE THEREOF | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000041647-A1 | SUSTAINED DELIVERY OF POLYIONIC BIOACTIVE AGENTS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-1999058640-A2 | MCT-1, A HUMAN ONCOGENE | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 1999-11-18 | — | — | WO | disclosed |
| WO-1999053961-A1 | PEPTIDES FOR EFFICIENT GENE TRANSFER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999053903-A1 | MICROSPHERES CONTAINING CONDENSED POLYANIONIC BIOACTIVE AGENTS AND METHODS FOR THEIR PRODUCTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-10-28 | — | — | WO | disclosed |
| EP-0910301-A1 | COMPOSITIONS AND METHODS FOR COATING MEDICAL DEVICES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997047254-A9 | COMPOSITIONS AND METHODS FOR COATING MEDICAL DEVICES | — | 1998-03-19 | — | — | WO | disclosed |
| WO-1997047254-A1 | COMPOSITIONS AND METHODS FOR COATING MEDICAL DEVICES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117976-B2 | Compositions and methods for regulating erythropoiesis | EPOR, CD47, CD44 | CA2 2524/4885LPAR3 1926/4885LPAR1 2387/4885 |
| US-20220242964-A1 | COMPOSITIONS AND METHODS FOR REGULATING ERYTHROPOIESIS | EPOR, CD47, CD44 | CA2 2524/4885LPAR3 1926/4885LPAR1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.